SCHEMBL4240375

SCHEMBL4240375

OCCNCc1cc(C(F)(F)F)ccc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.46
FEN1 P39748 1/20 0.46
TP53 P04637 1/20 0.43
HTR2A P28223 2/20 0.42
SLC6A4 P31645 2/20 0.42
KCNH2 Q12809 2/20 0.42
SCN9A Q15858 1/20 0.42
KMT2A Q03164 1/20 0.41
CYP1A2 P05177 3/20 0.41
CYP2D6 P10635 3/20 0.41
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KCNJ5 P48544 1/20 0.40
KCNJ3 P48549 1/20 0.40
CYP2C9 P11712 1/20 0.40
P2RX7 Q99572 2/20 0.39
EPHX2 P34913 1/20 0.39
MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236331 0.87 KCNH2 (0.48) TP53HTR2ASLC6A4KCNH2KMT2A
SCHEMBL4239870 0.86 KCNH2 (0.43) TP53HTR2ASLC6A4KCNH2KMT2A
SCHEMBL4241050 0.84 KCNH2 (0.45) TP53HTR2ASLC6A4KCNH2KMT2A
SCHEMBL7800566 0.81 CDK1 (0.52) TP53KMT2AALDH1A1LMNANPSR1
SCHEMBL25399129 0.78 CYP1A2 (0.56) KMT2ACYP1A2CYP2D6ALDH1A1LMNA
SCHEMBL1599550 0.78 TACR1 (0.54) TP53HTR2ASLC6A4KCNH2ALDH1A1
SCHEMBL92949 0.78 PDE2A (0.44) TP53HTR2ASLC6A4KCNH2KMT2A
SCHEMBL4235838 0.77 TACR1 (0.49) TP53HTR2ASLC6A4KCNH2KMT2A
SCHEMBL4244859 0.77 SLC6A4 (0.63) TP53HTR2ASLC6A4KCNH2CYP1A2
SCHEMBL80680 0.76 TRPV1 (0.42) TP53HTR2ASLC6A4KCNH2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137653-A1 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE INFLAYZME PHARMACEUTICALS LTD. (CA) 2009-05-28 US disclosed
EP-1871357-A2 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE Inflazyme Pharmaceuticals, Ltd. (CA) 2008-01-02 EP disclosed
WO-2006108149-A2 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE INFLAZYME PHARMACEUTICALS LTD. (CA) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137653-A1 SUBSTITUTED BENZYLAMINES AS CYP2A INHIBITORS AND USES THEREOF TO TREAT NICOTINE DEPENDENCE CYP2A6, CYP2B6, CYP2D6 ALOX5AP 1239/4885FEN1 2928/4885TP53 4337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.